

# WILL HE BE WEARING CHILDREN'S CLOTHES WHEN HE'S A 'GROWN-UP'?

## Prescribing Information

**Presentation** A vial of sterile lyophilised powder of somatrem corresponding to 4IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2ml ampoule of water for injections for use in the reconstitution of the injection.

**Uses** The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

**Dosage and Administration**  
**Route of administration:** By intramuscular injection. **Recommended dosage:** The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

**Contra-indications, warnings, etc.** Only patients with unfused epiphyses should be treated. Diabetes mellitus. **Precautions:** Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. **Side-effects:** Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

**Package Quantities** Combined package containing one vial of somatrem 4 IU and one ampoule of 2ml water for injections.

**Price** NHS Price £28.

**Further Information** Somatrem is the British Approved Name for methionyl human somatotropin. **Product Licence Number** 0022/0060

**KabiVitrum Limited.** Kabi-Vitrum House, Riverside Way, Uxbridge, Middx UB8 2YF.

**Product Authorisation Number** 187/28/1.

**Elre** KabiVitrum, Cahill May Roberts Ltd, P.O. Box 1090, Chapelizod, Dublin 20.



## Somatonorm® (somatrem)

is successfully changing the outlook for this child and thousands like him suffering from short stature caused by growth hormone deficiency (GHD).

With early diagnosis and treatment, GHD children can achieve a normal adult height. For the past two decades, KabiVitrum has pioneered growth hormone research. The introduction of Somatonorm ensures that, for the first time, sufficient growth hormone is available to treat all GHD children.



# HE WANTS TO GROW. KabiVitrum CAN HELP HIM.

# ABC OF COMPUTING

A J ASBURY

Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants to know how computers can contribute to his practice of medicine.

Price: Inland £6.50; Overseas £8.00\*/USA \$14.00\* (Inland £6.00; Overseas £7.50\*/USA \$13.00\* to BMA members)

\*including air mail postage

Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal

PO Box 295

London WC1H 9TE

or any leading bookseller



## This publication is available in microform.

University Microfilms

International reproduces this publication in microform: microfiche and 16mm or 35mm film. For information about this publication or any of the more than 13,000 titles

we offer, complete and mail the coupon to: University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106. Call us toll-free for an immediate response: 800-521-3044. Or call collect in Michigan, Alaska and Hawaii: 313-761-4700.

☐ Please send information about these titles:

Name \_\_\_\_\_  
Company/Institution \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ Zip \_\_\_\_\_  
Phone ( ) \_\_\_\_\_

University  
Microfilms  
International

### Abbreviated Prescribing

#### Information

'HUMULIN' S ▼ 'HUMULIN' I ▼  
'HUMULIN' Zn ▼ 'HUMULIN' M1 ▼  
'HUMULIN' M2 ▼ Human insulin (crb)

**Presentation:** Humulin S: A sterile, aqueous solution of human insulin (crb).

**Humulin I:** A sterile suspension of isophane human insulin (crb). **Humulin Zn:** A sterile suspension of crystalline human insulin (crb) zinc suspension.

**Humulin M1:** A sterile suspension of human insulin (crb) in the proportion of 10% soluble insulin and 90% isophane insulin. **Humulin M2:** A sterile suspension of human insulin (crb) in the proportion of 20% soluble insulin and 80% isophane insulin. Each presentation contains 100 IU/ml. **Uses:** For the treatment of insulin-dependent diabetes mellitus.

**Dosage and Administration:** The dosage should be determined by the physician, according to the requirements of the patient. Humulin S may be administered by subcutaneous, intramuscular or intravenous injection. Humulin I, Humulin Zn, Humulin M1 and Humulin M2 should be administered by subcutaneous or intramuscular injection only. Humulin S may be administered in combination with Humulin I or Humulin Zn as required. **Humulin I, Zn, M1 and M2:** Rotate vial in palms of hands immediately before use to resuspend.

**Mixing of insulins:** The shorter-acting insulin should be drawn into the syringe first, to prevent contamination of the vial by the longer-acting preparation. It is advisable to inject immediately after mixing. **Contra-indications, Warnings, etc. Contra-indications:** Hypoglycaemia. Under no circumstances should Humulin I, Humulin Zn, Humulin M1 or Humulin M2 be given intravenously.

**Precautions: Usage in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Transferring from other insulins:** A small number of patients transferring from insulins of animal origin may require a reduced dosage and/or a change in the ratio of soluble to intermediate preparations, especially if they are very tightly controlled and bordering on hypoglycaemia. The risk of hypoglycaemia can be considered minimal if the daily dosage is less than 40 IU. Insulin-resistant patients receiving more than 100 IU daily should be referred to hospital for transfer. **Side-effects:** Lipodystrophy, insulin resistance and hypersensitivity have rarely been reported. **Legal**

**Category: P. Package Quantities:** 10ml glass vials in packs of 5. **Price:** Humulin S: 100 IU/ml. £6.68; Humulin I: 100 IU/ml. £6.68; Humulin Zn: 100 IU/ml. £6.68; Humulin M1: 100 IU/ml. £6.68; Humulin M2: 100 IU/ml. £6.68. **Product Licence Numbers, Name and Address:** Humulin S 100 IU/ml 0006/0165 Humulin I 100 IU/ml 0006/0168 Humulin Zn 100 IU/ml 0006/0179 Humulin M1 100 IU/ml 0006/0199 Humulin M2 100 IU/ml 0006/0200. **Date of Preparation:** January 1986.

**References:** 1. Corcoran, J.S. and Yudkin, J.S. *Diabetic Medicine*, 1985, 2, 131-133. 2. Fineberg, S.E. *et al.* *Diabetologia*, 1983, 25, 465-469.

### Full Prescribing Information Available From:

Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA. Telephone: Basingstoke (0256) 473241.

\*'HUMULIN' is a Lilly trade mark

Hu 141 March 1986





# He's running on the new M2.

He has found that a B.D. dose of the new Humulin M2 closely matches his daily insulin requirements.

The 20/80 mixture of Humulin S (soluble) and Humulin I (isophane) provides both a rapid action and prolonged effect that fit his needs.

In another patient with a lower soluble insulin requirement, Humulin M1, containing 10% soluble and 90% isophane, might be more suitable.

All this with a consistency and



convenience that cannot usually be achieved with free mixing.<sup>1</sup>

Like all Humulin products, M1 and M2 share the unique benefits of human insulin produced by genetic engineering; low immunogenicity;<sup>2</sup> unlimited future supply and at a cost comparable with pork or enzymatically modified insulins.

**Humulin**  
Human insulin (crb)  
**MIXTURES**

Consistency and convenience with low immunogenicity





# Closeness counts.

Breast milk is best for babies. But if a mother is not breast feeding, baby needs a milk that is as close as possible to breast milk.

That's why Milupa were the first company in Britain to add taurine to all their babymilks. Taurine is an important amino acid, found in breast milk. By adding taurine, and all the other nutrients necessary for healthy growth, Milupa Babymilks have achieved a closeness to breast milk that counts.

There are two Milupa Babymilks. APTAMIL for a gentle start to bottle feeding, and MILUMIL, made to satisfy hungrier babies. Both taste and smell so pleasant, even the fussiest babies take to them easily. Because it is not just nutritional composition that matters, it's how babies respond, too. Both our babymilks are in granulated form, which makes them so easy to measure, mix and dissolve.

We know closeness counts.

**Milupa Babymilks. As close to breastmilk as babymilk can be.**

**IMPORTANT** Breast milk is the best milk for a baby. A doctor, midwife, nurse or health visitor should be consulted for any advice needed. If a babymilk is used it is important for the baby's health that all preparation instructions are followed carefully.

**milupa<sup>®</sup>**  
**Babymilks**

**Aptamil<sup>®</sup> & Milumil<sup>®</sup>**



## Paediatric Gastroenterology

Edited by **Charlotte M. Anderson** *et al*  
Second Edition, Early 1987. 1000 pages,  
282 illustrations. About £72.00

The new edition of this comprehensive reference text has been completely revised to incorporate important advances made in the past decade. It will continue to be the definitive source for all those studying disorders of the gastrointestinal tract in children.

## Essentials of Neonatal Medicine

**M.I. Levene** *et al*  
1987. 416 pages, 103 illustrations. Paper, about £10.50

The lucid instruction given in this book will appeal to junior hospital doctors, membership candidates, midwives and neonatal nurses. It covers all the situations likely to occur in hospital practice and explains the reasons behind the procedures.

## Nutrition and Feeding of Pre-term Infants

**B.A. Wharton**  
Early 1987. 256 pages, 8 illustrations. About £29.50

This book represents the conclusions of the Committee on Nutrition of the Preterm Infant of the European Society for Paediatric Gastroenterology and Nutrition. It provides essential information for this all-important aspect of the care of both sick and healthy preterm infants.

## Common Pediatric Problems

Edited by **R.A. Hoekelman** *et al*  
1987. 1800 pages, 450 illustrations. About £53.00

This comprehensive volume deals with the field of paediatrics from every angle, and the paediatrician will need to use no other reference text.

## Lecture Notes on Neonatology

**Gillian M. Gandy** and  
**N.R.C. Robertson**  
Early 1987. 352 pages, 44 illustrations. Paper, about £8.95

This book will fill the need for a comprehensive and up-to-date text for both students and those working towards a higher examination in paediatrics, and for nurses working in special care baby units.


## Clinical Paediatric Surgery: Diagnosis and Management

Edited by **P.G. Jones** and  
**A.W. Woodward**  
Third Edition, 1986. 588 pages, 142 illustrations. Paper, £25.00

'...strongly recommended...It comes from the staff of the Royal Children's Hospital, Melbourne, which has established itself as one of the leading paediatric centres of the world.....Results in brief — full marks!' *Archives of Disease in Childhood* (on the last edition)

**Blackwell Scientific Publications**  
Osney Mead, Oxford OX2 0EL

# Intel News Room



**Presentation** *Amphotericin B* is available in a variety of formulations for intravenous (IV) and intrathecal use. Uses include treatment of systemic mycoses. *Amphotericin B* is also available in a variety of formulations for topical use.

**Dosage and Administration** *Amphotericin B* is available in a variety of formulations for intravenous (IV) and intrathecal use. The dosage and administration of *Amphotericin B* is dependent on the formulation and the route of administration. For intravenous use, the dosage is typically 0.1 to 0.2 mg/kg/day. For intrathecal use, the dosage is typically 1 to 2 mg. For topical use, the dosage is typically 1 to 2 mg/day.

[illegible]

Pharmaceuticals: Esprit, Inc., 14401 N. 11th Ave., Div. 501, 12300, Road, Vancouver, British Columbia, V1V 0B6.

# Epilim<sup>®</sup>

sodium valproate

**Presentation 1.** Epilim 200 Enteric Coated. A lilac-coloured enteric coated tablet containing 200mg sodium valproate. **2.** Epilim 500 Enteric Coated. A lilac-coloured enteric coated tablet containing 500mg

sodium valproate. **3.** Epilim 100mg crushable tablets. A white scored tablet containing 100mg sodium valproate. **4.** Epilim Syrup. A red, cherry-flavoured syrup containing 200mg sodium valproate per 5ml. **5.** Epilim Liquid. A red, cherry-flavoured, sugar-free liquid containing 200mg sodium

valproate per 5ml. **Indications** In the treatment of generalised, partial or other epilepsies. In women of child-bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and**

**Administration** To be taken with or after food. Epilim may be given twice daily. Enteric coated tablets should be

swallowed whole. **Monotherapy Adults:** Start at 600mg/daily increasing by 200mg at 3 day intervals until control is achieved. (Maximum dose 2,500mg per day).

**Children over 20kg:** Initially 400mg/day with spaced increases until control is achieved. (Usually within the range 20-30mg/kg body weight per day).

**Children under 20kg:** 20mg/kg of body weight per day; in severe cases may be increased up to 40mg/kg day. Increases above this only if plasma valproic acid levels, clinical chemistry and haematological parameters can be monitored. **Combined**

**Therapy** It may be necessary to raise the dose when used with anticonvulsants which induce liver enzyme activity. Dosage of barbiturates should be reduced if sedation is observed. Optimum dosage is mainly determined by seizure control and routine measurement of plasma levels is unnecessary. **Contra-**

**indications, Warnings; Contra-indication:** Active liver disease. **Side effects:** Liver dysfunction including hepatic failure resulting in fatalities has occurred in patients whose treatment included valproic acid or sodium valproate. The incidents mainly occurred during the first 6 months of therapy. Clinical symptoms are more helpful than laboratory investigations in the early stages of hepatic failure. The onset of an acute illness, especially within the first 6 months, which may include symptoms of vomiting,

lethargy or weakness, drowsiness, anorexia, jaundice or loss of seizure control is an indication for immediate withdrawal of the drug. Evidence to date does not establish which investigation could predict this possible adverse effect: measurement of liver function should be performed in the first 6 months of therapy in those who seem most at risk. Hyperammonaemia without hepatic damage can occur, it is usually transient, but may occasionally present clinically. If so Epilim should be discontinued. Valproic acid inhibits platelet aggregation. Thrombocytopenia has been reported. Spontaneous bruising or bleeding is an indication for withdrawal of medication. Pancreatitis, tremor, weight gain, transient hair loss, increased alertness, aggressiveness, hyperactivity, amenorrhoea, stupor and oedema have been reported. **Drug Interactions** Epilim may potentiate monoamine oxidase inhibitors and other anti-depressants. Loss of efficacy of oral contraceptive agents does not appear to be a problem. **Women of Childbearing Age** Valproic acid and sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age the benefits of these compounds should be weighed against the possible hazard suggested by these findings and their pregnancies should be carefully monitored. **Product Licence**

**Numbers** Epilim 200 Enteric Coated 0623/0006. Epilim 500 Enteric Coated 0623/0005. Epilim 100mg crushable tablets 0623/0015. Epilim Syrup 0623/0004. Epilim Liquid 0623/0016.

**NHS Cost** Epilim 200 Enteric Coated 100 tablets, £6.59. Epilim 500 Enteric Coated 100 tablets, £16.45. Epilim 100mg crushable tablets 100 tablets, £3.99. Epilim Syrup 200ml, £4.03. Epilim Liquid 200ml, £4.03. Further information is available from:

Labaz: Sanofi UK Ltd., Floats Rd., Wythenshawe, Manchester M23 9NF. Tel: 061-945 4161.

## In a wide range of epilepsies




# Epilim<sup>®</sup>

sodium valproate

## helps to maintain the normality of life




# Simonsen & Weel care... about Neonates.




## **Monitoring for Neonates**

The introduction of the Neopack range of Neonatal monitors, each based on the unique Neoscope, now means that all known neonatal monitoring applications can be catered for. From the simple Diascope 1, through to the most sophisticated combinations of monitors from our extensive range of Simonsen & Weel monitors help to care for neonates.



## **Pulse Oximetry for Neonates**

With the purpose built neonatal sensor the Criticare is ideal for the continuous monitoring of oxygen saturation in the newborn. This simple to use reliable monitor, gives a clear digital display of the %O<sub>2</sub> Saturation and pulse rate, all in a compact, portable and mains/battery operated unit.



## **Incubators for Neonates**

A safe, stable controlled environment is needed for the premature infant. The Ameda range of incubators offers a wide choice, with the Amelette and Amecare. For those occasions when a closed incubator is not required the Ametherm represents a real alternative.

Simonsen & Weel Ltd,  
Ruxley Corner, Sidcup, Kent DA14 5BL.  
Tel: 01-309 0433. Telex: 896328.

# S&W

# International coverage of the most important developments in pediatric medicine

## PEDIATRIC RESEARCH

*An International Journal of Clinical, Laboratory, and  
Developmental Investigation*

Editor-in-Chief: Delbert A. Fisher, MD

Every month, **Pediatric Research** puts you in touch with leading authorities in pediatric pulmonology, endocrinology and metabolism, gastroenterology, and nutrition. You'll read about significant new clinical and laboratory results, as selected and reported by an international array of distinguished contributors and editors.

Abstracts of major society meetings worldwide and occasional supplements on specific issues in pediatric health are also part of the package, but the hallmark of **Pediatric Research** is *research*, and lots of it. Each issue contains some 15 original articles — 4 to 6 pages each — on late-breaking investigations into the most difficult problems of childhood disease.

Cystic fibrosis, hypopituitarism, sudden infant death syndrome, protein intolerance, metabolic disorders, and sickle cell anemia are just a few of the subjects covered in recent issues. As advances are made in the understanding and management of these and other baffling childhood disorders, **Pediatric Research** will continue to be there with timely, accurate, and useful reports from leaders in the field. **Monthly**

**Personal: \$95/yr Institutions: \$120/yr**  
**In-training: \$75/yr** (add \$15.00 outside the US)



**FOR FASTEST SERVICE**, call 1-800-638-6423  
**FREE** from anywhere in the US except AK. MD  
residents, call 528-4105 collect.



P.O. Box 23291 Baltimore, Maryland 21203  
266 Fulham Road London SW10 9EL England



## PEDIATRIC RESEARCH *An International Journal of Clinical, Laboratory, and Developmental Investigation*

**Research you can't afford to miss... and an offer you can't afford to pass up**

Avoid planned rate increases and ensure uninterrupted service by subscribing to **PEDIATRIC RESEARCH** for up to 3 years at current rates.

- |  |   |
|--|---|
| <input type="checkbox"/> New subscription  | <input type="checkbox"/> Renewal          |
| <input type="checkbox"/> 3 yrs   | <input type="checkbox"/> 2 yrs            |
| <input type="checkbox"/> 1 yr  |   |
| <input type="checkbox"/> <b>Personal: \$95/yr</b> <input type="checkbox"/> <b>Institutions: \$120/yr</b> |   |
| <input type="checkbox"/> <b>In-training: \$75/yr</b>   |   |
| (add \$15.00 outside the US)   |   |
| <input type="checkbox"/> check enclosed  | <input type="checkbox"/> bill me          |
| <input type="checkbox"/> VISA  | <input type="checkbox"/> MasterCard       |
| <input type="checkbox"/>   | <input type="checkbox"/> American Express |

card # \_\_\_\_\_ exp. \_\_\_\_\_  
signature P.O. # \_\_\_\_\_

**Williams & Wilkins**

MD residents, please add 5% sales tax. Subscriptions outside the US must be prepaid, in US dollars only. *Residents, fellows, interns and students*: when applying for the in-training rate, which is limited to three years, please include institution name and training status. Rates valid through October 31, 1987.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Name \_\_\_\_\_  
Address \_\_\_\_\_  
City State Zip \_\_\_\_\_

P.O. Box 23291 Baltimore, Maryland 21203  
266 Fulham Road London SW10 9EL England  
printed in USA



PORAD 94454 87

# Monatsschrift Kinder- heilkunde

Organ der  
Deutschen Gesellschaft  
für Kinderheilkunde

134. Band  
Heft 12  
Dezember 1986

Springer-Verlag  
Berlin Heidelberg New York London  
Paris Tokyo

|  | <b>Thema des Monats</b>   | <b>This Month's Topic</b>  |            |
|--|---|--|------------|
|  | Enzymurie zur Nierendiagnostik — Das C-reaktive Protein bei der Diagnose akuter und chronischer Krankheiten   | Urinary Enzymes and Renal Disease — The Significance of C-Reactive Protein for the Diagnosis of Acute or Chronic Disease   | 831        |
| J. H. H. Ehrich, U. Wurster, M. Lütge, I. Mertz, E. Doebring, B. Oemar | Enzymurie und Nierenerkrankungen im Kindesalter   | Urinary Enzymes and Renal Diseases in Children   | 832        |
| J. H. H. Ehrich, F. Krull, U. Peltner, A. Hussein, J. Stein            | Die Bedeutung des C-reaktiven Proteins für die pädiatrische Diagnostik  | The Diagnostic Significance of C-Reactive Protein in Diseases of Children  | 840        |
|  | <b>Pädiatrie aktuell</b>  | <b>Trends in Paediatrics</b>   | 847        |
|  | <b>Was hat das Kind?</b><br>Trainingsprogramm für die Weiterbildung zum Kinderarzt  | <b>What's Wrong with the Child?</b><br>Program for Continuing Education of Paediatricians  | 848        |
|  | <b>Aus Klinik und Forschung Originalien</b>   | <b>Clinic and Research Originals</b>   |            |
| R. Rosskamp, M. Becker, M. Zallett                                     | Zirkulierende Somatostatinkonzentrationen im Kindesalter  | Circulating Somatostatin Concentrations in Children  | 849        |
| K. Müller-Deile, G. Rupprath, J. Vogt                                  | Akut- und Langzeiteffekte von Captopril bei widerstandsbedingter pulmonaler Hypertonie im Kindes- und Jugendalter   | Acute and Long-Term Effects of Captopril on Pulmonary Hypertension in Children and Adolescents   | 854        |
| T. Kullmer, W. Kindermann  | Körpergewichtsunabhängige Ergometrieverfahren bei Kindern unter besonderer Berücksichtigung des Belastungsblutdruckverhaltens   | Ergometric Body Weight-Independent Procedures in Children with Special Consideration of Exercise Blood Pressure  | 858        |
| U. Dörr, M. Zieger   | Spinale Sonographie im Kindesalter  | Spinal Sonography in Childhood   | 864        |
|  | <b>Der interessante Fall</b>  | <b>Interesting Cases</b>   |            |
| Th. Zimmermann, K.-H. Deeg, H. P. Hümmer, B. Böwing                    | Die intralobäre Lungensequstration  | Intralobular Lung-Sequestration  | 869        |
| A. Richter, K. Heyne, J. Sagebiel, M. Weber                            | Respiratorischer Notfall beim Neugeborenen: extreme laryngo-tracheo-oesophageale Spalte (Oesophago-Trachea)   | Respiratory Emergency in the Newborn: Complete Laryngo-Tracheo-Oesophageal Cleft ("Oesophago-Trachea")   | 874        |
| R. Lohrer, L. Barran, St. Kellnar, B. H. Belohradsky                   | Atrophoderma idiopathica et progressiva Pasini et Pierini, eine wenig bekannte Form der zirkumskripten Sklerodermie im Kindesalter  | Atrophoderma Idiopathica et Progressiva Pasini et Pierini, a Rare Variety of Localized Scleroderma in Childhood  | 878        |
| R. Dettmann, P. E. Lange, J. H. Bürsch, P. H. Heintzen                 | Lungenembolie im jugendlichen Alter. Nachweis mit Hilfe der intravenösen digitalen Subtraktionsangiographie   | Pulmonary Embolism in Adolescents. Prove with Intravenous Digital Subtraction Angiography  | 881        |
|  | <b>Wußten Sie schon?</b>  | <b>Do You Know?</b>  |            |
| F. Bläker  | <i>Neues aus Therapie und Prophylaxe</i><br>Empfehlungen der Ernährungskommission der Deutschen Gesellschaft für Kinderheilkunde zur Einführung von Beikost in die Ernährung des Säuglings              | <i>New Developments in Therapy and Prophylaxis</i><br>Recommendations of the Subcommittee on Nutrition of the German Society of Paediatrics on the Introduction of Additional Food to the Feeding of Infants | 884        |
| O. Tönz, G. Schubinger   | Die Ernährung kleiner Frühgeborener mit FM <sub>85</sub> : energie-, protein- und mineralienverstärkte Frauenmilch  | Feeding of Small Prematures with FM <sub>85</sub> : Energy-Protein- and Mineral-Enriched Breast Milk   | 885        |
| K. Schneider, D. Knorr, O. Butenandt, H. Fendel                        | <i>Aus der Klinik — für die Klinik</i><br>Die connatale Hypothyreose — eine Diagnose aus der Abdomenleeraufnahme<br>Auflösung und Kommentar des Trainingsprogramms für die Weiterbildung zum Kinderarzt | <i>Practical Tips for Clinicians</i><br>Connatal hypothyroidism diagnosed by X-ray of the abdomen<br>Solution and Commentary in the Program for Continuing Education of Paediatricians                       | 887<br>883 |
|  | <b>Neue Bücher</b>  | <b>New Books</b>   | 889        |
|  | <b>Aus Gesellschaften und Berufsverband</b>   | <b>Society and Professional Organisations</b>  | 889        |
|  | <b>Tagesgeschichte, Personalia</b>  | <b>News of the Day, Personal News</b>  | 890        |
|  | <b>Tagungskalender</b>  | <b>Forthcoming Meetings</b>  | 890        |
|  | <b>Sachregister</b>   | <b>Subject Index</b>   | 891        |
|  | <b>Für die Dokumentation</b>  | <b>Documentation</b>   | A 54       |


*"Value judgements about food are being made all the time . . .*

# ABC OF NUTRITION

A STEWART TRUSWELL

*. . . they are nearly always subjective and usually wrong."*

A Stewart Truswell, Boden professor of human nutrition at the University of Sydney, separates fact from fallacy in the *ABC of Nutrition*, a collection of articles from the *BMJ*. This illustrated guide offers the general medical reader a refreshingly down to earth review of all aspects of nutrition – from anorexia to obesity, infant feeding to dietary guides for the elderly – and will be invaluable for any doctor wishing to advise his patients about their eating habits (or even to revise his own).



***Chapters include:***

- Nutrition for pregnancy
- Enteral and parenteral nutrition
- Vitamins
- Malnutrition in the third world
- Therapeutic diets
- Reducing the risk of coronary heart disease
- Food sensitivity

Price: Inland £4.95; Abroad £6.75/USA\$10.00

BMA members: Inland £4.45; Abroad £6.25/USA\$9.00

*(Please quote membership number). Prices include postage, by air abroad.*

*Payments must be enclosed with order.*

## BOOKS FROM THE BMJ

Order from British Medical Journal, PO Box 295, London WC1H 9TE  
or any leading bookseller

# HOW TO DO IT

SECOND EDITION


The first edition of HOW TO DO IT proved a useful and popular guide to those things a doctor needs to know but is rarely taught: how to take an examination, how to interview and be interviewed, how to plan and write up research, how to behave at an inquest. In the second edition the original chapters have been expanded and updated, and there are several more chapters on new challenges—choosing a computer, flying, holding a press conference—and on some older ones not included in the first edition—assessing a job, dealing with a publisher.

Price: Inland £6.95  
Abroad £9.00/USA\$14.50  
BMA members: Inland £6.45  
Abroad £8.50/USA\$13.50  
*including postage, by air  
abroad*



Please quote  
membership number

Payment must be enclosed  
with order

Order from  
British Medical Journal  
PO Box 295  
London WC1H 9TE  
or any leading bookseller







# Pure innovation revealed

## The range of human insulins from Nordisk and Wellcome



Full prescribing information available on request from either:-

Nordisk-UK  
Highview House  
Tattenham Crescent  
Epsom (KT18 5Q)  
Tel. No: Burgh Heath (07373) 60621

The Wellcome Foundation Ltd.  
Crewe Hall  
Crewe  
Cheshire CW11 0UB  
Tel. No: Crewe (0270) 583151

● **Human  
INSULATARD**  
(Isophane Insulin  
Injection [NPH],  
highly purified  
human insulin [emp])

● **Human  
VELOSULIN**  
(Neutral Insulin  
Injection, highly  
purified human  
insulin [emp])

● **Human  
MIXTARD 30/70**  
(Neutral suspension  
comprising 30% Neutral  
Insulin Injection and 70%  
Isophane Insulin  
Injection [NPH] - human  
insulin [emp])

● **Human  
INITARD 50/50**  
(Neutral suspension  
comprising 50% Neutral  
Insulin Injection and 50%  
Isophane Insulin  
Injection [NPH] - human  
insulin [emp])

**INITARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH]), HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50** are manufactured from highly purified human insulin (emp). **PRESENTATION** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. **USES** Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. **DOSAGE AND ADMINISTRATION** Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. **CONTRA-INDICATIONS AND WARNINGS** Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Initard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. **PHARMACEUTICAL PRECAUTION** Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. **LEGAL CATEGORY P BASIC NHS PRICE** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50: 10 ml vial £6.95. **PRODUCT LICENCE NUMBERS** Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Initard 50/50 3132/0040 and 0003/0214.